Antihypertensive Medications for Patients with End-Stage Renal Disease on Dialysis

First-Line Medication Options

• Beta-blockers and calcium channel blockers are the most effective antihypertensive medications for patients with end-stage renal disease (ESRD) on dialysis, with demonstrated benefits on cardiovascular outcomes and mortality, according to the Kidney International guidelines 1, 2
• The American Journal of Kidney Diseases recommends beta-blockers as first-line therapy for patients with previous myocardial infarction or established coronary artery disease 3
• Amlodipine reduced cardiovascular events compared with placebo in hemodialysis patients with hypertension in randomized controlled trials, as reported in Kidney International 1
• Calcium channel blockers are associated with decreased total and cardiovascular mortality in observational studies, according to the American Journal of Kidney Diseases 3

Second-Line Medication Options

• ACE inhibitors/ARBs may reduce left ventricular mass index according to meta-analyses, as reported in Kidney International 1
• ACE inhibitors/ARBs may preserve residual kidney function, especially in peritoneal dialysis patients, according to Kidney International 1
• The American Journal of Kidney Diseases recommends ACE inhibitors/ARBs as first-line treatment in the majority of patients 3
• Mineralocorticoid receptor antagonists have shown cardiovascular benefits with spironolactone versus placebo in some trials, as reported in Kidney International 1

Special Considerations

• The American Journal of Kidney Diseases suggests that achievement of dry weight and reduction of extracellular fluid volume should be pursued before or alongside medication therapy 3
• Salt restriction should be continuously emphasized as part of hypertension management, according to the American Journal of Kidney Diseases 3
• A reasonable goal for predialysis blood pressure is 140/90 mmHg (measured in sitting position), as recommended by the American Journal of Kidney Diseases 4
• The target should avoid substantial orthostatic hypotension or symptomatic intradialytic hypotension, according to the American Journal of Kidney Diseases 4

Treatment Algorithm

• Optimize volume status through dialysis and sodium restriction, as recommended by the American Journal of Kidney Diseases 3
• For patients with coronary artery disease or heart failure, start with beta-blockers, according to the American Journal of Kidney Diseases 3
• For patients without specific cardiovascular indications, start with calcium channel blockers, as reported in Kidney International 1
• If blood pressure remains uncontrolled, add a second agent from a different class, as recommended by the American Journal of Kidney Diseases 3

Common Pitfalls

• Failing to assess volume status before initiating or increasing antihypertensive medications, as warned by the American Journal of Kidney Diseases 4
• Overlooking the importance of preserving residual kidney function when selecting medications, as reported in Kidney International 1
• Not adjusting medication regimens to prevent intradialytic hypotension, as reported in Kidney International 2

Antihypertensive Treatment for Dialysis Patients with ESRD

Initial Management: Volume Control First

• The American Society of Nephrology recommends probing the prescribed target dry weight through gradual adjustments to identify true euvolemia in dialysis patients 5
• The National Kidney Foundation suggests restricting dietary sodium to 2-3 g/day with intensive patient education to control volume overload in dialysis patients 5
• Increasing dialysis treatment time and/or frequency can improve volume control in dialysis patients, according to the Kidney Disease Outcomes Quality Initiative 5

First-Line Pharmacological Agents

• The American College of Cardiology recommends beta-blockers as first-line antihypertensive agents for dialysis patients with cardiovascular disease, as they demonstrate the strongest evidence for reducing cardiovascular mortality and heart failure hospitalizations 5
• The European Society of Cardiology suggests that carvedilol reduces cardiovascular mortality in hemodialysis patients with dilated cardiomyopathy, but increases intradialytic hypotension risk 5
• The American Heart Association recommends using dialyzable beta-blockers, such as atenolol, for patients with frequent intradialytic hypotension, and non-dialyzable agents, such as carvedilol, for patients with stable intradialytic blood pressure 6

Second-Line Pharmacological Agents

• The American Society of Nephrology recommends ACE inhibitors and ARBs as second-line antihypertensive agents for dialysis patients, as they provide cardioprotective effects through left ventricular mass reduction and preservation of residual kidney function 5
• The National Kidney Foundation suggests that ACE inhibitors and ARBs may preserve residual kidney function, especially in peritoneal dialysis patients 5

Medication Timing and Administration

• The American College of Cardiology recommends administering antihypertensive medications preferentially at night to reduce nocturnal blood pressure surge and minimize intradialytic hypotension in dialysis patients 6
• The European Society of Cardiology suggests considering intradialytic blood pressure patterns when selecting between dialyzable and non-dialyzable agents 6

Blood Pressure Targets and Monitoring

• The American Society of Nephrology recommends targeting predialysis blood pressure <140/90 mmHg measured in sitting position, and avoiding targets that cause substantial orthostatic hypotension or symptomatic intradialytic hypotension 5, 6
• The National Kidney Foundation suggests performing extensive evaluation, including home blood pressure monitoring, and reassessing dry weight if systolic blood pressure rises >10 mm Hg from pre- to post-dialysis in at least 4 of 6 consecutive treatments 5, 6

Critical Pitfalls to Avoid

• The American College of Cardiology recommends never initiating or escalating antihypertensive medications without first assessing and optimizing volume status in dialysis patients 5, 6
• The American Society of Nephrology suggests avoiding non-dialyzable beta-blockers, such as carvedilol, in patients with frequent intradialytic hypotension 6

Timing of Antihypertensive Medications After Hemodialysis

Medication Timing Recommendations

• The American Society of Nephrology recommends that the timing of antihypertensive medications should be individualized based on intradialytic blood pressure patterns and the dialyzability of each specific agent, with carvedilol held before dialysis if intradialytic hypotension occurs frequently, while losartan, amlodipine, and isosorbide mononitrate can generally be given on a consistent schedule regardless of dialysis timing 7
• For patients with frequent intradialytic hypotension, consider administering losartan after dialysis to minimize hypotensive episodes during the session, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 7

Volume Status Optimization

• The National Kidney Foundation recommends that before adjusting medication timing or doses, ensure the patient is at true dry weight through adequate ultrafiltration and dietary sodium restriction (2-3 g/day), as volume overload underlies most cases of blood pressure elevation in dialysis patients 7

Critical Decision Algorithm

• If the patientogle patient has frequent intradialytic hypotension (systolic BP drops >20 mmHg or symptomatic hypotension during dialysis), hold carvedilol and isosorbide mononitrate before dialysis and administer both medications after the dialysis session, as suggested by the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) 7
• If systolic blood pressure rises >10 mmHg from pre- to post-dialysis in at least 4 of 6 consecutive treatments, perform extensive evaluation including home blood pressure monitoring and reassess dry weight before adjusting medications, according to the American Heart Association (AHA) 7